1 – 10 of 27
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Association between pre-biologic T2-biomarker combinations and response to biologics in patients with severe asthma
(
- Contribution to journal › Article
-
Mark
EUFOREA/EPOS2020 statement on the clinical considerations for CRSwNP care
(
- Contribution to journal › Article
- 2023
-
Mark
Is asthma's heterogeneity too vast to use traditional phenotyping for modern biologic therapies?
(
- Contribution to journal › Article
-
Mark
Biologics in severe asthma : A pragmatic approach for choosing the right treatment for the right patient
(
- Contribution to journal › Article
-
Mark
Comparative effectiveness of Anti-IL5 and Anti-IgE biologic classes in patients with severe asthma eligible for both
(
- Contribution to journal › Article
-
Mark
Impact of Inititing Biologics in Patients With Severe Asthma on Long-term Oral Corticosteroids or Frequent Rescue Steroids (GLITTER): Data From the International Severe Asthma Registry
(
- Contribution to journal › Article
-
Mark
Identifying Predictors of First-Line Subcutaneous TNF-Inhibitor Persistence in Patients with Inflammatory Arthritis : A Decision Tree Analysis by Indication
(
- Contribution to journal › Article
-
Mark
Eosinophils—from cradle to grave
(
- Contribution to journal › Article
- 2022
-
Mark
Health-Care and Societal Costs Associated with Non-Persistence with Subcutaneous TNF-α Inhibitors in the Treatment of Inflammatory Arthritis (IA) : A Retrospective Observational Study
(
- Contribution to journal › Article
-
Mark
Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis
(
- Contribution to journal › Article